Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,035 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.
Fusco JP, Castañón E, Carranza OE, Zubiri L, Martín P, Espinós J, Rodríguez J, Santisteban M, Aramendía JM, Gil-Bazo I. Fusco JP, et al. Among authors: martin p. J Neurooncol. 2013 Dec;115(3):429-35. doi: 10.1007/s11060-013-1241-0. Epub 2013 Sep 15. J Neurooncol. 2013. PMID: 24037499
Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.
Arévalo E, Castañón E, López I, Salgado J, Collado V, Santisteban M, Rodríguez-Ruiz M, Martín P, Zubiri L, Patiño-García A, Rolfo C, Gil-Bazo I. Arévalo E, et al. Among authors: martin p. J Transl Med. 2014 Apr 14;12:98. doi: 10.1186/1479-5876-12-98. J Transl Med. 2014. PMID: 24726028 Free PMC article.
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
Castañón E, Rolfo C, Viñal D, López I, Fusco JP, Santisteban M, Martin P, Zubiri L, Echeveste JI, Gil-Bazo I. Castañón E, et al. Among authors: martin p. J Transl Med. 2015 Aug 7;13:257. doi: 10.1186/s12967-015-0622-x. J Transl Med. 2015. PMID: 26248464 Free PMC article.
Patterns of progression in patients treated for immuno-oncology antibodies combination.
Bernard-Tessier A, Baldini C, Castanon E, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C, Ammari S. Bernard-Tessier A, et al. Among authors: martin p. Cancer Immunol Immunother. 2021 Jan;70(1):221-232. doi: 10.1007/s00262-020-02647-z. Epub 2020 Jul 22. Cancer Immunol Immunother. 2021. PMID: 32700090 Free PMC article. Clinical Trial.
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.
Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C. Bernard-Tessier A, et al. Among authors: martin p. Eur J Cancer. 2018 Sep;101:160-164. doi: 10.1016/j.ejca.2018.06.005. Epub 2018 Jul 30. Eur J Cancer. 2018. PMID: 30071444
8,035 results